In conclusion, our results indicate that EGFR-TKI rechallenge after first-line EGFR-TKI treatment in elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations was effective and tolerable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.